The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

LADA (Latent Autoimmune Diabetes in Adults) — Comprehensive

Slowly Progressive Type 1 Diabetes in Adulthood

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Endokrinoloji department. Book Appointment →

What is LADA (Latent Autoimmune Diabetes in Adults) — Comprehensive?

Latent autoimmune diabetes in adults (LADA) represents 4-12% of all adult-onset diabetes cases (mistakenly diagnosed as type 2 in many).

Definition criteria (Immunology of Diabetes Society): age over 30 at diagnosis, presence of at least one islet autoantibody (GADA most common), no insulin requirement for at least 6 months after diagnosis.

Pathogenesis: T-cell mediated autoimmune destruction of beta cells, slower than type 1 due to lower autoantibody titers and partial preserved insulin secretion.

Genetic risk: HLA-DR3/DR4 alleles (similar to type 1) plus type 2 risk genes (TCF7L2).

Higher GADA titers correlate with faster beta-cell decline and earlier insulin requirement.

Spectrum disorder: bridges classical type 1 and type 2 diabetes phenotypes.

Symptoms

Adult onset (over 30) with initial response to oral antidiabetic agents.
Gradual loss of glycemic control over months to years on oral therapy.
Non-obese or normal-weight phenotype (in contrast to typical type 2).
Negative or absent metabolic syndrome features.
Polyuria, polydipsia, and weight loss when beta-cell failure progresses.
Personal or family history of autoimmune diseases (thyroid, celiac, vitiligo, pernicious anemia).
Ketosis or DKA may develop after initial honeymoon phase.
Failure to maintain HbA1c target despite multiple oral agents.

Risk Factors

Personal or family history of type 1 diabetes or other autoimmune diseases.
Adult-onset diabetes with non-obese phenotype.
Rapid progression to insulin requirement on oral agents.
HLA-DR3 or HLA-DR4 haplotypes.
Female predominance (slightly).
European ancestry (lower prevalence in non-European populations).

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Adult-onset diabetes failing oral therapy within 1-3 years.
  • Diabetes diagnosis with personal autoimmune history.
  • Non-obese diabetes patient with rapid HbA1c deterioration.
  • Family history of type 1 diabetes in adult-onset diabetes case.
  • Ketosis-prone diabetes in non-classical type 1 age group.
  • Genetic counseling for family screening if multiple autoimmune diseases present.

Treatment Methods

01
Confirm diagnosis with GAD antibody testing (also IA-2, ZnT8 if GADA negative); C-peptide measurement.
02
Early insulin therapy is recommended (preserves beta-cell function and improves long-term outcomes).
03
Avoid sulfonylureas as monotherapy (accelerate beta-cell exhaustion).
04
Metformin and DPP-4 inhibitors may be used in early stages with caution.
05
GLP-1 receptor agonists may have beta-cell protective effects (limited LADA-specific evidence).
06
Continuous glucose monitoring and HbA1c targets individualized (under 7.0% generally).
07
Screen for associated autoimmune diseases: TSH, anti-TPO, anti-tTG, B12 levels.
08
Cardiovascular risk reduction: statin, antihypertensive, antiplatelet as indicated.
09
Multidisciplinary care: endocrinology, dietitian, diabetes educator, psychology support.
10
Patient education on autoimmune nature, insulin transition, and complication prevention.

Which Department to Visit?

You can visit our Endokrinoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Endokrinoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

LADA (Latent Autoimmune Diabetes)

Endokrinoloji

LADA is a latent autoimmune form of diabetes that begins in adulthood, behaves initially like type 2 diabetes but is autoimmune in origin and progresses to insulin dependence over years.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.